Vladimír Študent, MD, PhD, FEBU

Dpt.of Urology, robotic surgeon, University hospital Olomouc, CZE

[Urology Times @UrologyTimes]

The @US_FDA has granted tentative approval to an abbreviated new drug application for generic enzalutamide tablets in 40-mg, 80-mg, 120-mg, and 160-mg strengths. #pcsm https://t.co/2QtfjvL9hH

[Tom Powles @tompowles1]

Thanks to the huge number of people @Annals_Oncology including authors, reviews, editors/staff and patients. An impact factor of 80 makes it an attractive & efficient place to broadcast practice informing/changing oncology trials and biomarker data. Thanks 🙏 again to everyone @myESMO @ESMO_Open @FAndreMD @DrChoueiri @stolaney1 @FilippoPietran4 @bradleymonk3 @peters_solange https://t.co/S4fdlWU5Ma

[Axel S. Merseburger @amerseburger]

One of the most thought-provoking slides at #ASCO26. Dr. Reimers outlines a future MIBC paradigm where cCR, ctDNA and utDNA guide decisions between cystectomy, bladder preservation and surveillance after EV+pembrolizumab. Smarter treatment, less overtreatment. #ASCO26 @OncoAlert

[Enrique Grande @drenriquegrande]

⚡️ Phase 3 LITESPARK-022 in high-risk ccRCC after nephrectomy: adjuvant pembrolizumab + belzutifan vs pembrolizumab alone (n=1,841).

24-month DFS: 80.7% vs 73.7% (HR 0.72; P=0.0003).

First phase 3 adjuvant trial to demonstrate DFS benefit vs pembrolizumab monotherapy — a potential new standard of care.

#KidneyCancer

https://t.co/Y0gVbiAUDG

[Radha Tripathi @Radha_AI]

A man spends 50 years teaching at MIT.

He knows his time is running out.

So he records one last lecture — everything he knows, distilled into a single hour.

He died 5 months later.

This is that lecture.

The most important hour you'll watch this week. 👇
Bookmark it for later

[Michael Hofman @DrMHofman]

First images from the GE Omni 128 cm Total Body PET/CT 🚀

The new scanner detected a <5 mm local recurrence of prostate cancer missed by standard PSMA PET/CT - despite 79% shorter acquisition ⏱️

Delayed imaging boosted lesion uptake and informed dose-painted salvage RT 🎯

@JournalofNucMed @PeterMacCC @declangmurphy @_ShankarSiva
https://t.co/Kiq9PHC12X

[Declan Murphy @declangmurphy]

RAMPP trial out in @EUplatinum. Radical prostatectomy for oligometastic cancer improves cancer specific mortality. Important work. https://t.co/KEb9WXIpCN

[European Urology @EUplatinum]

🌍 EAU Policy on Telesurgery
European Urology publishes the first structured policy on telesurgery in urology.

🔹 Patient safety & ethics first
🔹 Governance, training, and consent standards
🔹 Oversight through audits & registries

📖 European Urology 2025;88:318–324
👉 https://t.co/RKjsxi2LSH

[Journal of Urology @JUrology]

Extended pelvic lymph node dissection remains a valuable staging tool in radical prostatectomy. New findings suggest a potential role in reducing metastatic progression—but emphasize the need for individualized decision-making amid ongoing debate

More 👉 https://t.co/TrRA5t6vL5

[European Urology @EUplatinum]

🧬 New Platinum Opinion in #EuropeanUrology: Defining indolent #prostatecancer requires a multidisciplinary approach. The Genitourinary & Urological Pathology Societies call for improved classification to reduce overdiagnosis & overtreatment.
🔗 https://t.co/GzUvkFsF29
#UroOncology #ActiveSurveillance #Pathology

[Karim Touijer @TouijerKarim]

For the 3rd consecutive year MSK- Urology is the number 1 urology service by the U.S. News &amp; World Report.

Congratulations to our doctors, nurses, PAs, admin staff and everyone in the clinical care team.

To our patients, thank you for your trust
@UrologyMSK

[European Urology @EUplatinum]

🤖 Time for a new PARADIGM? Kasivisvanathan et al. outline how AI could revolutionize #prostatecancer diagnosis on MRI. The PARADIGM trial will provide level 1 evidence on AI's role in detecting clinically significant disease.
🔗 https://t.co/Tlesx10JKW
#AI #UroOncology #ProstateMRI #OncoTwitter #EuropeanUrology

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Breaking News from ph3 Embark trial👉Enzalutamide+ADT improve overall survival (OS) vs. ADT alone in Non-Metastatic HSPC #Prostatecancer Congrats to @SFreedlandMD @nealshore &amp; team! Earlier enza works better! Link👉 https://t.co/nTWHrnnbTZ @OncoAlert @urotoday @PCFnews

[𝙍𝙞𝙘𝙘𝙖𝙧𝙙𝙤 𝘽𝙚𝙧𝙩𝙤𝙡𝙤 MD PhD @RicBertolo]

‼️new study by @UniVerona #urology team‼️

We explored effects of early vs delayed ureteral ligation during #RARC: early ligation associated with ⬆️ risk of functional decline, with significantly ⬆️ chance of ≥25% reduction in eGFR and eGFR &lt;60 ml/min (HR 10.3 and 7.3, p&lt;0.04)

[Uromigos @Uromigos]

The highlight of #ASCO25 was the AMPLITUDE trial presented by @AttardLab on PARPi in HRR altered mHSPC. Listen to our podcast discussing these practice-changing data!

https://t.co/M9O3T9F7pH

[tombal @BertrandTOMBAL]

Patience and resilience are the bedrock of every academic triumph. But none of this would exist without the trust of our patients, the dedication of our nurses, and the relentless support of the EORTC HQ team. The spotlight belongs to you, not us. I love you all…@EORTC

[European Urology @EUplatinum]

Editorial - How To Write a Response to Reviewers by @VickersBiostats et al

Read the full article here: https://t.co/ON3OR5KQLF

#UroSoMe #MedTwitter #Editorial #EurUrol

[Yüksel Ürün @DrYukselUrun]

Game-changer in prostate cancer risk stratification!
PSMA-PET isn’t just for staging—it predicts survival.
@EUplatinum @APCCC_Lugano @Uroweb @PCFnews @ProfKHerrmann @DrMHofman
https://t.co/HGDYhdY8zW

[Fakultní nemocnice Olomouc @fnolomouc]

Naše robotické centrum má posilu – druhý robotický operační systém da Vinci Xi. Díky němu se roční počet roboticky asistovaných operací zvýší ze zhruba 500 na téměř 1000. https://t.co/pCIzhhf6nt